These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38162505)

  • 1. Long-term survival in a patient with primary refractory AML after salvage allogeneic hematopoietic transplantation and post-transplant localized irradiation and venetoclax maintenance: a case report.
    Fan Y; Wang L; Chen B; Zhang J; Yang L; Qiu X; Jiang H; Zhu L; Wang C; Xu Y
    Front Oncol; 2023; 13():1329858. PubMed ID: 38162505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of AML Relapse After Allo-HCT.
    Webster JA; Luznik L; Gojo I
    Front Oncol; 2021; 11():812207. PubMed ID: 34976845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML.
    Cao XY; Chen JQ; Wang H; Ma W; Liu WW; Zhang FF; Xue S; Dong L; Liu T; Zhao XZ; Liu CC; Xu X; He Y; Wang L; Wang JL
    Ann Med; 2023 Dec; 55(1):388-400. PubMed ID: 36629738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of a Second Allogeneic Hematopoietic Cell Transplant in Relapsed Acute Myeloid Leukemia: Results of a Systematic Review and Meta-Analysis.
    Kharfan-Dabaja MA; Reljic T; Yassine F; Nishihori T; Kumar A; Tawk MM; Keller K; Ayala E; Savani B; Mohty M; Aljurf M; Saber W
    Transplant Cell Ther; 2022 Nov; 28(11):767.e1-767.e11. PubMed ID: 35970301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Wei Y; Xiong X; Li X; Lu W; He X; Jin X; Sun R; Lyu H; Yuan T; Sun T; Zhao M
    Cancer Sci; 2021 Sep; 112(9):3636-3644. PubMed ID: 34185931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
    Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse.
    Kharfan-Dabaja MA; Labopin M; Polge E; Nishihori T; Bazarbachi A; Finke J; Stadler M; Ehninger G; Lioure B; Schaap N; Afanasyev B; Yeshurun M; Isaksson C; Maertens J; Chalandon Y; Schmid C; Nagler A; Mohty M
    JAMA Oncol; 2018 Sep; 4(9):1245-1253. PubMed ID: 30003233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia.
    Yan CH; Liu QF; Wu DP; Zhang X; Xu LP; Zhang XH; Wang Y; Huang H; Bai H; Huang F; Ma X; Huang XJ
    Biol Blood Marrow Transplant; 2017 Aug; 23(8):1311-1319. PubMed ID: 28483716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Impact of disease status on outcomes of allogeneic hematopoietic stem cell transplantation in patients with refractory and relapsed acute myeloid leukemia].
    Zhou QL; Tang XW; Sun AN; Qiu HY; Jin ZM; Miao M; Fu ZZ; Zhao BR; Shi XL; Chen GH; Wu DP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):954-8. PubMed ID: 22931663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant.
    Bewersdorf JP; Derkach A; Gowda L; Menghrajani K; DeWolf S; Ruiz JD; Ponce DM; Shaffer BC; Tamari R; Young JW; Jakubowski AA; Gyurkocza B; Chan A; Xiao W; Glass J; King AC; Cai SF; Daniyan A; Famulare C; Cuello BM; Podoltsev NA; Roshal M; Giralt S; Perales MA; Seropian S; Cho C; Zeidan AM; Prebet T; Stein EM; Tallman MS; Goldberg AD; Stahl M
    Leuk Lymphoma; 2021 Dec; 62(14):3394-3401. PubMed ID: 34477024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repetitively Administered Low-Dose Donor Lymphocyte Infusion for Prevention of Relapse after Allogeneic Stem Cell Transplantation in Patients with High-Risk Acute Leukemia.
    Tsirigotis P; Gkirkas K; Kitsiou V; Chondropoulos S; Athanassiades T; Thomopoulos T; Tsirogianni A; Stamouli M; Karagiannidi A; Siafakas N; Pappa V; Nagler A
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34070786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions.
    Ortí G; Sanz J; García-Cadenas I; Sánchez-Ortega I; Alonso L; Jiménez MJ; Sisinni L; Azqueta C; Salamero O; Badell I; Ferra C; de Heredia CD; Parody R; Sanz MA; Sierra J; Piñana JL; Querol S; Valcárcel D
    Exp Hematol; 2018 Jun; 62():24-32. PubMed ID: 29526774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of CLAE Chemotherapy Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Leukemia].
    Tao SD; Song LX; Deng Y; Chen Y; Zhang X; Ding BH; Wang CL; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):677-684. PubMed ID: 37356926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage hematopoietic stem cell transplantation for patients with higher leukemia burden in relapsed or refractory acute myeloid leukemia: a ten-year study.
    Jiang S; Lu X; Wei R; Zhang A; Chen H; Shi W; Xia L
    Ann Hematol; 2023 Nov; 102(11):3205-3216. PubMed ID: 37682324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of second allogeneic stem cell transplantation and anti-relapse strategies in patients with relapsed/refractory acute myeloid leukemia: A unicentric retrospective analysis.
    Shumilov E; Hasenkamp J; Maulhardt M; Mazzeo P; Schmidt N; Boyadzhiev H; Jung W; Ganster C; Haase D; Koch R; Wulf G
    Hematol Oncol; 2022 Oct; 40(4):763-776. PubMed ID: 35368106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of chemotherapy combined with donor lymphocyte infusion on chronic graft-versus-host disease and prognosis in minimal residual disease positive patients after allogeneic hematopoietic stem cell transplantation].
    Shi YX; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YY; Liu KY; Huang XJ; Mo XD
    Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):713-719. PubMed ID: 31648470
    [No Abstract]   [Full Text] [Related]  

  • 17. Optimized therapeutic strategy for patients with refractory or relapsed acute myeloid leukemia: long-term clinical outcomes and health-related quality of life assessment.
    Yan CH; Wang Y; Sun YQ; Cheng YF; Mo XD; Wang FR; Chen YH; Zhang YY; Han TT; Chen H; Xu LP; Zhang XH; Liu KY; Huang XJ
    Cancer Commun (Lond); 2022 Dec; 42(12):1387-1402. PubMed ID: 36274263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Sequential intensified conditioning followed by graft-versus-leukemia induction could prevent relapse of refractory acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
    Xuan L; Fan Z; Zhang Y; Huang F; Dai M; Li Y; Nie D; Lin D; Jiang Q; Sun J; Xiao Y; Liu Q
    Zhonghua Yi Xue Za Zhi; 2015 Jun; 95(24):1915-20. PubMed ID: 26710693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy.
    Gyurkocza B; Lazarus HM; Giralt S
    Bone Marrow Transplant; 2017 Aug; 52(8):1083-1090. PubMed ID: 28244979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy.
    Zuanelli Brambilla C; Lobaugh SM; Ruiz JD; Dahi PB; Goldberg AD; Young JW; Gyurkocza B; Shaffer BC; Ponce DM; Tamari R; Sanchez Escamilla M; Castillo Flores N; Politikos I; Scordo M; Shah GL; Cho C; Lin RJ; Maloy MA; Devlin SM; Jakubowski AA; Berman E; Stein EM; Papadopoulos EB; Perales MA; Tallman MS; Giralt SA; Smith M
    Transplant Cell Ther; 2021 Sep; 27(9):771.e1-771.e10. PubMed ID: 34033977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.